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Abstract In blood-borne metastasis, intravasated metastatic
tumor cells are thought to localize at the target site via a series of
processes involving platelet aggregation, adhesion to endothe-
lium, and invasion through the basal membrane. In the present
study, we examined how platelet aggregation contributes to the
trafficking of metastatic tumor cells in vivo by use of an inhibitor
of platelet aggregation. Highly invasive B16BL6 melanoma cells
were labeled with [2-18F]2-fluoro-2-deoxy-D-glucose and injected
into mice to determine cell trafficking non-invasively by positron
emission tomography. Both platelet aggregation inhibitor
cyclo(RSarDPhg), which could not inhibit metastasis, and
metastatic inhibitor cyclo(GRGDSPA) suppressed the accumu-
lation of B16BL6 cells in the lung by about 12%, suggesting that
platelet aggregation partly affects cell trafficking but not to a
great extent, and that platelet aggregation is not the essential
step for B16BL6 cell arrest in targets.
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1. Introduction
Complex multiple processes are known to be responsible for
the formation of metastasis of blood-borne tumor cells. How-
ever, the contribution of each event such as platelet aggrega-
tion, invasion, and adhesion to extracellular matrices (ECM)
to metastatic cell tra⁄cking has not been fully understood
because of a lack of methodology to determine cell tra⁄cking
non-invasively. Using positron emission tomography (PET),
we recently developed a non-invasive method to analyze
real-time metastatic tumor cell tra⁄cking [1]. In the present
study, the e¡ect of inhibitors of metastatic processes, namely,
one for platelet aggregation and the other for invasion, on
tumor cell tra⁄cking was investigated. A previous study
showed that cyclic RGD-Phenylglycine had a strong inhibi-
tory activity toward tumor cell-induced platelet aggregation,
although it had no anti-metastatic e¡ect nor inhibited adhe-
sion to ECM [2]. We employed a cyclic octapeptide dimer of
R-Sarcosine-D-Phenylglycine (RSarDPhg), cyclo(RSarDPhg),
in the present study instead of cyclic RGD-Phenylglycine.
Another inhibitor, cyclo(GRGDSPA) [3], is active toward
metastatic cell adhesion to basal membranes. It contains the
cell adhesion recognition domain of ¢bronectin, i.e. the RGD
sequence. This peptide caused a signi¢cant reduction in meta-
stasis, as well as in cell adhesion to ¢bronectin and vitronectin
in vitro at a low dose in comparison with that induced by
linear GRGDSPA [3]. Here, we determined the e¡ect of these
peptides on tra⁄cking of the highly lung-metastatic and in-
vasive B16BL6 melanoma. The results indicate how tumor
cell-induced platelet aggregation contributes to metastatic
cell tra⁄cking.
2. Materials and methods
2.1. Cells
B16BL6 melanoma cells, a highly lung-metastatic subline of B16
cells, were cultured in Dulbecco’s modi¢ed Eagle and Ham’s F12
(1:1) medium supplemented with 10% fetal calf serum (JRH Bioscien-
ces, Lenexa, KS) under a humidi¢ed atmosphere of 5% CO2 in air.
For PET experiment, the cells were labeled with [2-18F]2-£uoro-2-de-
oxy-D-glucose ([2-18F]FDG) by the method described previously [4].
In brief, B16BL6 cells were washed with glucose-free medium and
incubated with [2-18F]FDG for 30 min at 37‡C. After removal of
the free [2-18F]FDG, the cells were detached from the plate with
EDTA solution to obtain a single cell suspension. The size of single
cells determined after EDTA treatment was 17.6 þ 1.6 Wm. Cells of
less than 15 passage levels were used in all experiments.
2.2. Adhesion assay
Adhesion of the melanoma cells to ¢bronectin was determined as
described previously [3]. In brief, ¢bronectin was coated onto tissue
culture wells for 30 min at 37‡C, and BSA was added to each well.
Melanoma cells (1U105) were added to each well and incubated for
1 h at 37‡C in the presence or absence of various concentrations of
peptides. Adhering cells after having been washed with PBS were
trypsinized and counted. Thus, ¢fty percent inhibition dose was cal-
culated.
2.3. Platelet aggregation assay
Platelet aggregation assay was performed as described previously
[2]. In brief, human platelet-rich plasma was obtained from healthy
volunteers. The plasma (200 Wl) was incubated for 2 min in a cuvette
under constant stirring in an aggregometer (SSR Engineering Co.
Model PAT-2A) after the addition of 25 Wl of PBS or peptides diluted
with PBS. Then, 25 Wl of ADP solution was added, and the change in
light transmittance was monitored for 10 min. Thus, ¢fty percent
inhibition dose was calculated.
2.4. Metastasis assay
B16BL6 melanoma cells (1U105 cells/100 Wl) were co-injected with
100 Wl of peptide solution (1 mg peptides) or 100 Wl of PBS into
syngeneic 7-week-old C57BL/6 female mice (six per group, Japan
SLC, Inc.) via a tail vein. Fourteen days after the injection, the lungs
were excised, and the number of metastatic colonies on the lung sur-
face was counted.
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Fig. 1. PET images of B16BL6 melanoma cell accumulation in mice in the presence of cyclo(RUDPhg) or cyclo(GRGDSPA). a: Accumulation
of [2-18F]FDG-labeled B16BL6 cells in mice after co-injection with 1 mg of cyclo(RSarDPhg) (middle panel) or injection of cells only (upper
panel). Imaging by PET was done as described in Section 2. Images show the accumulation of the cells in lungs, liver, and kidney during
30 min after the administration of them. The upper and middle panels show PET images of mice injected with [18F]FDG-labeled B16BL6 cells,
and the lower one shows X-ray CT images of a mouse of similar age presented as a reference for the PET images. b: Accumulation of
[2-18F]FDG-labeled B16BL6 cells in lungs of mice treated or not with cyclo(RSarDPhg) or cyclo(GRGDSPA), each at 1 mg. Images show the
status of the accumulation of the cells every 15 min till 90 min after the injection of them. The three panels show PET images of lungs of mice
injected with [18F]FDG-labeled B16BL6 cells (upper), or the cells plus cyclo(RSarDPhg) (middle) or cyclo(GRGDSPA) (lower).
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2.5. PET analysis
Melanoma cells labeled with [2-18F]FDG (7.5U105 cells in 150 Wl
DME/F12 medium, 555^925 kBq) were mixed with 1.5 mg (150 Wl)
inhibitory peptides or with control peptide composed of 20 amino
acid residues derived from c-fos just prior to injection, and 200 Wl
of the mixed suspension was co-injected into 10-week-old C57BL/6
female mice via a tail vein under anesthesia induced with sodium
pentobarbital. Thus, the ¢nal amounts of cells and peptides injected
were 5U105 and 1 mg per mouse, respectively. Control mice were
each injected with 5U105 cells in 200 Wl of the above medium. The
emission scan of PET was started immediately after injection of the
cells and performed for 120 min with an animal PET camera (Hama-
matsu Photonics, SHR-2000) having a resolution of 2.7 mm. PET
images were simultaneously obtained in 14 slices with 3.25-mm aper-
tures where the 6th slice was settled at the xiphisternum. The radio-
activity in the form of coincidence gamma photons was measured and
converted to Bq/cm3 of tissue volume by calibration after correction
for decay and attenuation. A time-activity curve was obtained from
the mean pixel radioactivity in the region of interest (ROI) of the
composed PET images. The injected dose in each experiment was
normalized as 740 kBq throughout the whole study. After every
PET measurement, animals were killed for removal of organs and
counting of the radioactivity in these organs with an auto gamma
counter to con¢rm the accumulation of cells in each organ. The
ROI value of each organ correlated with the result of the direct
counting of the radioactivity in each organ. The viability of the re-
maining cells (i.e. not injected) after administration of the cells was
determined at 2 h after initiation of the PET scan by trypan blue dye
exclusion, and was more than 90%.
2.6. X-ray CT
X-ray CT images of 10-week-old mouse were obtained with slice
distances of 3.2 mm.
3. Results
Tumor cell-induced platelet aggregation is thought to play
an important role in the metastatic pathway [5]. The precise
time schedule for platelet aggregation is unknown, however.
Therefore, we investigated the e¡ect of cyclo(RSarDPhg), an
inhibitor of tumor cell-induced platelet aggregation, on cell
tra⁄cking. Characteristics of peptides tested in this experi-
ment are as follows: Fifty percent suppression doses of cell
adhesion to ¢bronectin by cyclo(GRGDSPA) or by cyclo-
(RSarDPhg) were 10 WM and over 200 WM, and those of
platelet aggregation induced by ADP were 9.0 WM and
0.1 WM, respectively. When inhibitory e¡ect of the peptides
on metastasis was evaluated by the reduction of lung coloni-
zation number as described in Section 2.4, cyclo(GRGDSPA)
having the RGD sequence caused 54.7% reduction, possibly
due to their inhibition of cell adhesion to the ECM, whereas
cyclo(RSarDPhg) did not cause any reduction of tumor meta-
stasis.
The e¡ect of cyclo(RSarDPhg), as well as that of cyclo-
(GRGDSPA), on B16BL6 cell tra⁄cking was analyzed by
PET. Fig. 1a shows the typical images for the ¢rst 30 min
of B16BL6 cell accumulation in mice after injection of the
cells. As shown in the ¢gure, B16BL6 cells accumulated
mainly in lungs. B16BL6 cells also accumulated mainly in
lungs when they were co-injected with either cyclo(RSarDPhg)
(Fig. 1a) or cyclo(GRGDSPA) (data not shown). Since the
metastatic cells mainly accumulated in lung tissue, time-de-
pendent changes in the accumulation in the lungs was deter-
mined. Fig. 1b shows the cumulative images for every 15 min
of B16BL6 cell accumulation in the lungs after injection of the
cells. Cell accumulation in this organ decreased time depend-
ently. The accumulation of B16BL6 cells in the lungs was
slightly suppressed in the presence of both kind of peptides.
We also examined the e¡ect of synthetic peptide composed of
20 amino acids derived from the c-fos product on the tra⁄ck-
ing, and this peptide did not a¡ect the accumulation of
B16BL6 cells in the lungs (data not shown). The FDG re-
leased by the corruption of cells in vivo is known to be dis-
tributed immediately to the liver and kidney but not to the
lungs [1,4].
Fig. 2a summarizes the ROI mean of every 10 min obtained
from four independent experiments and also shows the rela-
tive ROI mean for B16BL6 cells in the presence of cy-
clo(RSarDPhg) against that obtained for B16BL6 cells alone.
The values did not change throughout each PET scan,
suggesting that cyclo(RSarDPhg) suppressed lung accumula-
tion of B16BL6 to some extent immediately after injection
and that the suppressing activity did not change for at
least 90 min. Fig. 2b shows the data of a similar experi-
ment in which cyclo(RSarDPhg) was replaced with cyclo-
(GRGDSPA). Cyclo(GRGDSPA) also suppressed lung accu-
mulation of B16BL6 to some extent and the suppressing ac-
tivity did not change for at least 90 min.
4. Discussion
Tumor cell-induced platelet aggregation is considered to be
involved in the metastatic pathway as follows: (1) tumor cell
arrest in the vasculature; (2) promotion of tumor cell extra-
vasation; (3) enhancement of tumor cell adhesion to extra-
cellular matrix; and (4) stimulation of tumor cell prolifera-
tion. Intravasated metastatic tumor cells lead to local
metastasis through induction of platelet aggregation, adhesion
to the vessel endothelium, and invasion into local tissues. The
rate of each of these processes, however, is not known. One
reason is that there was previously no suitable non-invasive
method to determine cell tra⁄cking without changing the
physiological conditions. We previously established a method
that enables real-time analysis of cell movement in vivo from
immediately after injection in a living animal by use of PET
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Fig. 2. Relative accumulation of 18F in lungs during every 10 min
after injection of mice with [2-18F]FDG-labeled B16BL6 cells mixed
with cyclo(RSarDPhg) or cyclo(GRGDSPA). Time-activity curves
of 18F in lungs of separate experiments (n = 4) after injection of
[2-18F]FDG-labeled B16BL6 cells treated (closed bar) or not (open
bar) with 1 mg of cyclo(RSarDPhg) (a) or 1 mg of cyclo-
(GRGDSPA) (b) were obtained. The average accumulation of 18F
per min was calculated from every 10-min accumulation of 18F ex-
cept immediately after injection in which case 2-min to 10-min accu-
mulation of 18F was used. Percent accumulation of 18F was then
calculated where the 100% accumulation was used as the ¢rst
10-min accumulation of 18F in the control mice. Relative accumula-
tion of B16BL6 cells treated with the peptides against the control
was also calculated for each point time after the injection (U). Sig-
ni¢cant di¡erence against control; *, P6 0.05.
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[1,4]. In this current study, we investigated the e¡ect of inhib-
itors of the processes of blood-borne metastasis on tumor cell
tra⁄cking.
Integrin KIIbL3 is thought to be involved in tumor cell-
induced platelet aggregation, and thus RGD-related peptides
may inhibit tumor cell-induced platelet aggregation via bind-
ing to the integrin on platelets [6,7]. In the RGD sequence, the
structure of the guanidium and carboxylate groups of Arg and
Asp, respectively, with a restricted distance is thought to be
important [8]. Interestingly, among the compounds having
such a structure, cyclo(RSarDPhg) has inhibitory activity to-
ward platelet aggregation but no anti-metastatic activity.
Therefore, we investigated the e¡ect of this peptide on the
tumor cell tra⁄cking. Cyclo(RSarDPhg) caused a slight re-
duction in the lung accumulation of B16BL6 cells. The evi-
dence indicated that platelet aggregation is a fast event after
intravasation of tumor cells.
Cyclo(RSarDPhg) has no anti-metastatic potential, whereas
cyclo(GRGDSPA) does. Therefore, the metastasis of B16BL6
melanoma is not inhibited by the inhibition of platelet aggre-
gation alone. In other words, tumor cell-induced platelet ag-
gregation may not be an essential step for establishment of
metastasis, at least in the case of B16BL6 melanoma meta-
stasis, as it was previously suggested [2]. The result of B16F10
melanoma cell movement determined by in vivo videomicros-
copy also indicated that platelet did not appear to play any
role in the cell arrest [9]. Some previous reports, however,
showed that tumor cell-induced platelet aggregation is critical
for metastasis establishment. In fact, tumor cell-induced pla-
telet aggregation-inhibiting agents [10], peptides [11], or anti-
body [12,13] have been known to suppress tumor metastasis.
Similarly, lipopolysaccharide-induced platelet starvation re-
duced the metastatic potential of murine ¢brosarcoma [14].
Therefore, it is possible that platelet aggregation plays an
important role in establishment of metastasis of some tumors,
but not essential to some other tumors such as B16BL6. It is
also possible that 1 mg cyclo(RSarDPhg) is not enough to
suppress platelet aggregation in vivo. However, this is unlikely
because cyclo(RSarDPhg) slightly but signi¢cantly reduced
tumor cell arrest in the target tissues, suggesting that the pep-
tide actually a¡ected cell tra⁄cking.
The RGD sequence is known as a recognition domain of
¢bronectin, and is also a ligand for various integrins such as
K5L1, KvL3, KIIbL3, K2L1, KvL1, KvL5, KvL6, and K3L1 [15^
17]. RGD-related peptides are also noted for their anti-meta-
static e¡ect. The anti-metastatic action of RGD and related
peptides is thought to be based on inhibition of adhesion and
that of angiogenesis. Interestingly, cyclo(GRGDSPA) inhib-
ited lung accumulation of B16BL6 to the similar extent as
cyclo(RSarDPhg) did. Since the platelet aggregation-inhibit-
ing activity of cyclo(RSarDPhg) is about 90-fold stronger
than that of cyclo(GRGDSPA), cyclo(GRGDSPA) may in-
hibit lung accumulation by a di¡erent mechanism, although
it is also possible that 1 mg/mouse of cyclo(GRGDSPA) is
enough to reduce platelet aggregation and that the 12% re-
duction in B16BL6 accumulation in the lungs by either pep-
tide was caused by the inhibition of platelet aggregation, since
cyclization of RGD-related peptide increases the inhibitory
activity towards platelet aggregation [3]. Alternatively, cyclo-
(GRGDSPA) may inhibit lung accumulation through sup-
pression of the interaction between B16BL6 cells and endo-
thelial cells of lung capillaries. In fact, a recent study showed
that cyclic RGD inhibited the function of integrin K4L1,
which ligand is on the endothelium [18]; and in another study,
a di¡erent kind of RGD-related peptide, trimesyl(GRGDS)3,
which also had anti-metastatic activity, was not observed to
a¡ect tumor cell tra⁄cking [19].
In spite of the strong inhibitory activity of cyclo-
(GRGDSPA) against metastasis, the lung accumulation of
B16BL6 melanoma cells was only slightly a¡ected by the com-
pound. Therefore, the population of cells that undergo extra-
vasation may be rather small in the early stage, and invasion
may proceed mainly at a later stage. This is consistent with
the data reported by Koop and co-workers that more than
80% of melanoma cells survived and extravasated in the chick
embryo chorioallantoic membrane at 24 h after i.v. injection
[20].
As shown in Fig. 2, B16BL6 cells that had accumulated in
the lungs were released from this location time dependently.
Part of this loss may have been due to disruption of the cells
by immunity, although the release of [2-18F]FDG from intact
cells may also have contributed to the decrease in 18F in the
lung tissue. High accumulation of metastatic cells in the lungs
after injection may indicate the mechanical retardation of cell
£ow in the lungs because the lungs are the ¢rst organ through
which i.v. injected cells pass. The di¡erence in accumulation
between that in the presence of metastasis inhibitors and that
in the absence of them, however, suggests that some interac-
tions between metastatic cells and target organ, rather than
platelet aggregation, a¡ect the cell tra⁄cking.
Acknowledgements: We thank Mr. Takeharu Kakiuchi for the techni-
cal assistance. This research was supported in part by a Grant-in-Aid
for Scienti¢c Research from the Ministry of Education, Science, and
Culture of Japan.
References
[1] Oku, N., Koike, C., Sugawara, M., Tsukada, H., Irimura, T. and
Okada, S. (1994) Cancer Res. 54, 2573^2576.
[2] Isoai, A., Ueno, Y., Giga-Hama, Y., Goto, H. and Kumagai, H.
(1992) Cancer Lett. 65, 259^264.
[3] Kumagai, H., Tajima, M., Ueno, Y., Giga-Hama, Y. and Ohba,
M. (1991) Biochem. Biophys. Res. Commun. 177, 74^82.
[4] Koike, C., Oku, N., Watanabe, M., Tsukada, H., Kakiuchi, T.,
Irimura, T. and Okada, S. (1995) Biochim. Biophys. Acta 1238,
99^106.
[5] Oleksowicz, L. and Dutcher, J.P. (1995) Med. Oncol. 12, 95^102.
[6] Tang, D.G., Onoda, J.M., Steinert, B.W., Grossi, I.M., Nelson,
K.K., Umbarger, L., Diglio, C.A., Taylor, J.D. and Honn, K.V.
(1993) Int. J. Cancer 54, 338^347.
[7] Chiang, H.S., Yang, R.S. and Huang, T.F. (1995) Br. J. Cancer
71, 265^270.
[8] Hardan, I., Weiss, L., Hershkoviz, R., Greenspoon, N., Alon, R.,
Cahalon, L., Reich, S., Slavin, S. and Lider, O. (1993) Int. J.
Cancer 55, 1023^1028.
[9] Morris, V.L., Schmidt, E.E., Koop, S., MacDonald, I.C., Grat-
tan, M., Khokha, R., McLane, M.A., Niewiarowski, S., Cham-
bers, A.F. and Groom, A.C. (1995) Exp. Cell Res. 219, 571^578.
[10] Tzanakakis, G.N., Agarwal, K.C. and Vezeridis, M.P. (1993)
Cancer 71, 2466^2471.
[11] Tuszynski, G.P., Rothman, V.L., Deutch, A.H., Hamilton, B.K.
and Eyal, J. (1992) J. Cell. Biol. 116, 209^217.
[12] Toyoshima, M., Nakajima, M., Yamori, T. and Tsuruo, T.
(1995) Cancer Res. 55, 767^773.
[13] Kato, Y., Fujita, N., Yano, H. and Tsuruo, T. (1997) Cancer
Res. 57, 3040^3045.
[14] Kimoto, M., Ando, K., Koike, S., Matsumoto, T., Jibu, T.,
Moriya, H. and Kanegasaki, S. (1993) Clin. Exp. Metastasis
11, 285^292.
FEBS 20207 7-5-98 Cyaan Magenta Geel Zwart
C. Koike et al./FEBS Letters 427 (1998) 286^290 289
[15] Elices, M.J., Urry, L.A. and Hemler, M.E. (1991) J. Biol. Chem.
112, 169^181.
[16] Busk, M., Pytera, R. and Sheppard, D. (1992) J. Biol. Chem. 267,
5790^5796.
[17] Cardarelli, P.M., Yamagata, S., Taguchi, I., Gorcsan, F.,
Chiang, S. and Lobl, T. (1992) J. Biol. Chem. 267, 23159^23164.
[18] Cardarelli, P.M., Cobb, R.R., Nowlin, D.M., Scholz, W., Gorc-
san, F., Moscinski, M., Yasuhara, M., Chiang, S.L. and Lobl,
T.J. (1994) J. Biol. Chem. 269, 18668^18673.
[19] Saiki, I., Koike, C., Obata, A., Fujii, H., Murata, J., Kiso, Ha-
segawa, A., Komazawa, H., Tsukada, H., Azuma, I. Okada, S.
and Oku, N. (1996) Int. J. Cancer, 65, 833^839.
[20] Koop, S., MacDonald, I.C., Luzzi, K., Schmidt, E.E., Morris,
V.L., Grattan, M., Khokha, R., Chambers, A.F. and Groom,
A.C. (1995) Cancer Res. 55, 2520^2523.
FEBS 20207 7-5-98 Cyaan Magenta Geel Zwart
C. Koike et al./FEBS Letters 427 (1998) 286^290290
